Increased growth hormone response to sumatriptan challenge in adult autistic disorders

Sherie Novotny; Eric Hollander; Andrea Allen; Serge Mosovich; Bonnie Aronowitz; Charles Cartwright; Concetta DeCaria; Rima Dolgoff-Kaspar

doi:10.1016/S0165-1781(00)00134-7

Increased growth hormone response to sumatriptan challenge in adult autistic disorders

Sherie Novotny, Eric Hollander, Andrea Allen, Serge Mosovich, Bonnie Aronowitz, Charles Cartwright, Concetta DeCaria, Rima Dolgoff-Kaspar

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Serotonergic (5-HT) abnormalities have been documented in autism. To assess sensitivity of the 5-HT1d receptor, growth hormone response to the 5-HT1d receptor agonist sumatriptan was studied in adult autistic patients and matched normal controls. In this study, 11 adult patients with autism or Asperger's disorder were compared with nine matched controls. All subjects were randomized to single dose sumatriptan (6 mg SQ) and placebo challenges, separated by a 1-week interval, and growth hormone was measured before and during the challenges. The results showed a highly significant diagnosisxdrugxtime interaction on repeated measure analysis covaried for baseline. This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects. Therefore, abnormalities in 5-HT regulation in autism may be related to increased sensitivity of the 5-HT1d inhibitory receptor in autism.

Original language	English
Pages (from-to)	173-177
Number of pages	5
Journal	Psychiatry Research
Volume	94
Issue number	2
DOIs	https://doi.org/10.1016/S0165-1781(00)00134-7
State	Published - 15 May 2000

Keywords

Asperger's disorder
Autism
Growth hormone
Serotonin
Sumatriptan

Access to Document

10.1016/S0165-1781(00)00134-7

Cite this

@article{45c61fac3d3c4589b41f0ab355fc7b62,

title = "Increased growth hormone response to sumatriptan challenge in adult autistic disorders",

abstract = "Serotonergic (5-HT) abnormalities have been documented in autism. To assess sensitivity of the 5-HT1d receptor, growth hormone response to the 5-HT1d receptor agonist sumatriptan was studied in adult autistic patients and matched normal controls. In this study, 11 adult patients with autism or Asperger's disorder were compared with nine matched controls. All subjects were randomized to single dose sumatriptan (6 mg SQ) and placebo challenges, separated by a 1-week interval, and growth hormone was measured before and during the challenges. The results showed a highly significant diagnosisxdrugxtime interaction on repeated measure analysis covaried for baseline. This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects. Therefore, abnormalities in 5-HT regulation in autism may be related to increased sensitivity of the 5-HT1d inhibitory receptor in autism.",

keywords = "Asperger's disorder, Autism, Growth hormone, Serotonin, Sumatriptan",

author = "Sherie Novotny and Eric Hollander and Andrea Allen and Serge Mosovich and Bonnie Aronowitz and Charles Cartwright and Concetta DeCaria and Rima Dolgoff-Kaspar",

note = "Funding Information: This research was supported in part by the Seaver Foundation, a grant from Glaxo Wellcome Pharmaceuticals, grant 5 MO1 RR00071 for the Mount Sinai General Clinical Research Center from the National Center for Research Resources, National Institutes of Health, by a postdoctoral fellowship from the National Alliance for Autism Research.",

year = "2000",

month = may,

day = "15",

doi = "10.1016/S0165-1781(00)00134-7",

language = "English",

volume = "94",

pages = "173--177",

journal = "Psychiatry Research",

issn = "0165-1781",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Increased growth hormone response to sumatriptan challenge in adult autistic disorders

AU - Novotny, Sherie

AU - Hollander, Eric

AU - Allen, Andrea

AU - Mosovich, Serge

AU - Aronowitz, Bonnie

AU - Cartwright, Charles

AU - DeCaria, Concetta

AU - Dolgoff-Kaspar, Rima

N1 - Funding Information: This research was supported in part by the Seaver Foundation, a grant from Glaxo Wellcome Pharmaceuticals, grant 5 MO1 RR00071 for the Mount Sinai General Clinical Research Center from the National Center for Research Resources, National Institutes of Health, by a postdoctoral fellowship from the National Alliance for Autism Research.

PY - 2000/5/15

Y1 - 2000/5/15

N2 - Serotonergic (5-HT) abnormalities have been documented in autism. To assess sensitivity of the 5-HT1d receptor, growth hormone response to the 5-HT1d receptor agonist sumatriptan was studied in adult autistic patients and matched normal controls. In this study, 11 adult patients with autism or Asperger's disorder were compared with nine matched controls. All subjects were randomized to single dose sumatriptan (6 mg SQ) and placebo challenges, separated by a 1-week interval, and growth hormone was measured before and during the challenges. The results showed a highly significant diagnosisxdrugxtime interaction on repeated measure analysis covaried for baseline. This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects. Therefore, abnormalities in 5-HT regulation in autism may be related to increased sensitivity of the 5-HT1d inhibitory receptor in autism.

AB - Serotonergic (5-HT) abnormalities have been documented in autism. To assess sensitivity of the 5-HT1d receptor, growth hormone response to the 5-HT1d receptor agonist sumatriptan was studied in adult autistic patients and matched normal controls. In this study, 11 adult patients with autism or Asperger's disorder were compared with nine matched controls. All subjects were randomized to single dose sumatriptan (6 mg SQ) and placebo challenges, separated by a 1-week interval, and growth hormone was measured before and during the challenges. The results showed a highly significant diagnosisxdrugxtime interaction on repeated measure analysis covaried for baseline. This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects. Therefore, abnormalities in 5-HT regulation in autism may be related to increased sensitivity of the 5-HT1d inhibitory receptor in autism.

KW - Asperger's disorder

KW - Autism

KW - Growth hormone

KW - Serotonin

KW - Sumatriptan

UR - http://www.scopus.com/inward/record.url?scp=0034656974&partnerID=8YFLogxK

U2 - 10.1016/S0165-1781(00)00134-7

DO - 10.1016/S0165-1781(00)00134-7

M3 - Article

C2 - 10808042

AN - SCOPUS:0034656974

SN - 0165-1781

VL - 94

SP - 173

EP - 177

JO - Psychiatry Research

JF - Psychiatry Research

IS - 2

ER -

Increased growth hormone response to sumatriptan challenge in adult autistic disorders

Abstract

Keywords

Access to Document

Fingerprint

Cite this